论文部分内容阅读
This study observed the changes in somatosensory evoked potentials between patients with amyotrophic lateral sclerosis (ALS) and healthy controls to evaluate the function of the central deep somatosensory pathway. In patients with ALS, 28 patients (54%) showed an abnormality in somatosensory evoked potentials. All had abnormal lower limb somatosensory evoked potentials. Compared with healthy controls, the abnormality in somatosensory evoked potential was characterized by prolonged N20, P2, N2 latency and central conduction time, with or without a decrease in wave amplitude or disappearance of waveform. Results showed marked alterations in the somatosensory evoked potential in cortical components of the upper and lower limb in 54% of patients with ALS, and confirmed that patients with ALS may also have a defective deep somatosensory pathway, particularly an abnormal central deep somatosensory pathway.
This study observed the changes in somatosensory evoked potentials between patients with amyotrophic lateral sclerosis (ALS) and healthy controls to evaluate the function of the central deep somatosensory pathway. In patients with ALS, 28 patients (54%) showed an abnormality in somatosensory evoked potentials . All had abnormal lower limb somatosensory evoked potentials. Compared with healthy controls, the abnormality in somatosensory evoked potential was characterized by prolonged N20, P2, N2 latency and central conduction time, with or without a decrease in wave amplitude or disappearance of waveform. Results showed marked alterations in the somatosensory evoked potential in cortical components of the upper and lower limb in 54% of patients with ALS, and confirmed that patients with ALS may also have defective air somatosensory pathway, particularly an abnormal central deep somatosensory pathway.